Canopy Growth Corp (CGC) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Canopy Growth Corp (CGC) stock forecast summary
On Oct. 16, 2026, CGC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
Canopy Growth Corp is a small-cap company with a market capitalization of $302M. It ranks number 6 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For CGC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CGC included.
Follow CGC freeCGC price chart and AI forecast
How CGC ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Canopy Growth Corp (CGC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric. Statement values were filed in CAD and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | CGC | Rank |
|---|---|---|
| Market Cap | $302M | 6/29 |
| P/B Ratio | 0.62x | 9/13 |
| EPS | $-0.50 | – |
| Book Value/Share | $1.15 | – |
| Revenue/Share | $0.62 | – |
| FCF/Share | $-0.14 | – |
Profitability & Margins
| Metric | CGC | Rank |
|---|---|---|
| ROE | -34.3% | 10/16 |
| ROA | -21.4% | 15/25 |
| ROIC | -17.2% | 15/21 |
| Gross Margin | 38.7% | 11/23 |
| Operating Margin | -45.0% | 18/24 |
| Net Margin | -65.8% | 17/22 |
| EBT Margin | -65.9% | 19/25 |
| Tax Rate | 0.2% | – |
Financial Health
| Metric | CGC | Rank |
|---|---|---|
| Current Ratio | 3.04x | 7/29 |
| Quick Ratio | 2.39x | 6/26 |
| D/E Ratio | 0.60x | 9/17 |
| Financial Leverage | 1.60x | 9/17 |
| Interest Coverage | -1.7x | 12/22 |
| Working Capital | $239M | 7/29 |
Cash Flow
| Metric | CGC | Rank |
|---|---|---|
| Operating Cash Flow | -$57M | 27/30 |
| Free Cash Flow | -$60M | 12/12 |
| Capital Spending | -$3M | 4/12 |
| FCF/Sales | -23.2% | 11/12 |
| CapEx/Sales | 1.3% | 7/12 |
Operational Efficiency
| Metric | CGC | Rank |
|---|---|---|
| Asset Turnover | 0.32x | 16/17 |
| Receivables Turnover | 11.0x | 11/16 |
| Inventory Turnover | 2.0x | 18/21 |
| Fixed Assets Turnover | 1.1x | 16/17 |
| Days Sales Outstanding | 33 days | 6/16 |
| Days Inventory | 178 days | 2/20 |
| Payables Period | 48 days | 12/18 |
| Cash Conversion Cycle | 164 days | 2/12 |
Income Statement
| Metric | CGC | Rank |
|---|---|---|
| Total Revenue | $259M | 7/18 |
| Operating Income | -$117M | 24/28 |
| Net Income | -$171M | 22/25 |
| SG&A Expense | $117M | 4/16 |
| Cost of Goods Sold | $159M | 5/24 |
Dividend & Shareholder Information
| Metric | CGC | Rank |
|---|---|---|
| Shares Outstanding | 423M | – |
Balance Sheet Highlights (USD millions, converted from CAD)
| Total Current Assets | $357M | 45.9% of assets |
| Cash & Short-term Investments | $237M | 30.5% of assets |
| Accounts Receivable | $23M | 2.9% of assets |
| Inventory | $76M | 9.7% of assets |
| Total Liabilities | $293M | 37.6% of assets |
| Short-term Debt | $97M | 12.5% of assets |
CGC quarterly financials and insider trading
Canopy Growth Corp (CGC) industry peers
Companies classified under the same SEC industry code as Canopy Growth Corp (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CGC Canopy Growth Corp | ▶ | $302M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▲ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▼ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▲ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▼ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▶ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▶ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where CGC sits on the market map
Canopy Growth Corp (CGC) stock news
Loading...
Canopy Growth Corp (CGC) stock forecast FAQ
What is the Canopy Growth Corp (CGC) stock forecast?
On Oct. 16, 2026, CGC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Canopy Growth Corp stock predictions?
For CGC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Canopy Growth Corp forecasts updated?
Canopy Growth Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Canopy Growth Corp's industry peers?
33 issuers in our coverage, CGC included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Glass House Brands Inc. (GLAS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.